Type 2 responses determine skin rash during recombinant interleukin-2 therapy

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Cutaneous adverse drug reactions (CADRs) are common, causing patient burden.
• Aldesleukin (recombinant interleukin-2) causes skin rashes, leading to its therapeutic drawback.
• Understanding aldesleukin-induced skin rash mechanisms is crucial for new therapies.

Purpose of the Study:

• To develop a hypothetical immune-related adverse outcome pathway (irAOP) for aldesleukin-induced skin rash.
• To identify key cells and molecules involved in these CADRs.
• To provide a basis for predicting and preventing skin side effects in IL-2-based therapies.

Main Methods:

• Literature-based development of a hypothetical irAOP.
• Hypothesizing the predominant immune response type (Type 2).
• Identifying key cellular players: T-helper and innate lymphoid cells.

Main Results:

• A hypothetical irAOP for aldesleukin-induced skin rash was proposed.
• The study hypothesizes a Type 2 immune response driven by specific immune cells.
• Potential mechanisms beyond the irAOP were discussed.

Conclusions:

• The proposed irAOP offers a framework to understand aldesleukin-induced skin rash.
• This pathway may help in developing predictive models for CADRs.
• Further research can refine understanding and prevention of IL-2-related skin toxicities.